Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS – [Cloned #5940]
Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS Obstructive hypertrophic cardiomyopathy (HCM) is a disease state that has experienced a boom in progress during recent years. Chief among these advances, in terms of improving patient outcomes, has been the cardiac myosin inhibitor class, which recently received endorsement […]
Newly reported from EULAR 2024: Long COVID Linked to Significantly Worse Rheumatic Disease Activity
Newly reported from EULAR 2024: Long COVID Linked to Significantly Worse Rheumatic Disease Activity COVID-19 has demonstrated a substantial impact on patients with inflammatory arthritis, with those experiencing “long COVID” showing a significantly worse disease activity in addition to worse disability, pain, fatigue, and quality of life. Additionally, even those without long COVID had worse […]
News Coverage from EULAR 2024: Arthritis Disease Severity Peaks in Spring and Fall, According to PROs
News Coverage from EULAR 2024: Arthritis Disease Severity Peaks in Spring and Fall, According to PROs A seasonal correlation with patient-reported outcomes (PROs) were impacted by factors like sleep and fatigue among a group of patients with arthritis, with worse disease severity linked to spring and fall months, according to research presented at the 2024 European Congress […]
Broadcasting from EULAR 2024: Anxiety Plays a Significant Role in Physical Activity Avoidance Among Patients with PsA
Broadcasting from EULAR 2024: Anxiety Plays a Significant Role in Physical Activity Avoidance Among Patients with PsA Patients with psoriatic arthritis (PsA) were more likely to avoid physical activity based on anxiety symptoms and physical function, as opposed to disease activity, according to data presented at the 2024 European Congress of Rheumatology (EULAR) conference. “According to EULAR recommendations, […]
Newly reported from EULAR 2024: Ketogenic Diet Intervention Improves Psoriatic Arthritis Symptoms
Newly reported from EULAR 2024: Ketogenic Diet Intervention Improves Psoriatic Arthritis Symptoms A very low-calorie ketogenic diet (VLCKD) resulted in improvements in skin and joint disease activity, lipid profile, and significant weight loss among overweight patients with psoriatic arthritis (PsA). The 9-week diet intervention was both well-tolerated and effective, although those with higher disease activity at […]
Reporting from EULAR 2024: Gout Remission Achieved in Approximately Half of Patients Treated with Pegloticase
Reporting from EULAR 2024: Gout Remission Achieved in Approximately Half of Patients Treated with Pegloticase In a post hoc analysis of the MIRROR randomized controlled trial, 47% of patients with gout treated with pegloticase over 52 weeks were able to achieve remission. These data revealed patients may benefit from being treated with the drug longer than 6 […]
Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch A real-world study showed patients with inflammatory bowel disease (IBD) or chronic inflammatory rheumatic disease treated with reference adalimumab who were switched to the biosimilar CT-P17 generally believed the switch was a treatment necessity. Higher satisfaction rates were observed among those who were […]
News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months
News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence, as well as equivalent efficacy, safety, and immunogenicity compared with the reference product among a cohort of postmenopausal women with osteoporosis for up to 18 months of treatment, according to […]
Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren’s Treatment
Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren’s Treatment In an interview with HCPLive, Jacques-Eric Gottenberg, MD, PhD, associated with the Department of Rheumatology at Strasbourg University Hospital, France, discusses the results of a study presented at the 2024 European Congress of Rheumatology (EULAR) evaluating the efficacy and […]
Broadcasting from EULAR 2024: Dotinurad Demonstrates Superiority to Febuxostat for the Treatment of Gout
Broadcasting from EULAR 2024: Dotinurad Demonstrates Superiority to Febuxostat for the Treatment of Gout Among a cohort of Chinese patients with gout, dotinurad 4 mg demonstrated superiority to febuxostat 40 mg in lowering serum uric acid (sUA), according to data presented at the 2024 European Congress of Rheumatology (EULAR). Additionally, dotinurad 2 mg was non-inferior to febuxostat and […]
